Back to Search
Start Over
Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim.
- Source :
- Journal of Clinical Apheresis; 2005, Vol. 20 Issue 3, p129-136, 8p
- Publication Year :
- 2005
-
Abstract
- Mobilization of CD34<superscript>+</superscript> into peripheral blood is attained by either glycosylated (lenograstim) or non-glycosylated recombinant G-CSF (filgrastim). 101 donors, 57 males, median age 42 years (range 16-63) entered this retrospective study. Group I (55 cases) received filgrastim and group II lenograstim subcutaneously for 5-6 days. The peak number of CD34<superscript>+</superscript> cells/μl blood observed on day 4 and 5 was not significantly different in the two groups. No differences were shown in terms of both circulating CFU-GM at the time of harvesting and CD34<superscript>+</superscript> target of collection. The most frequent side effects were bone pain (18.2% grade I; 36.4% grade II, 7.3% grade III), headache (18.2%), nausea (9.1%), fever (5.5%) and a mild splenomegaly (>2cm) (5.5%) in filgrastim group, and bone pain (37.0% grade I, 26.1% grade II, 2.2% grade III), headache (17.4%), nausea (15.2%), fever (4.4%) and a mild splenomegaly (4.3%) in lenograstim group, respectively. CD34<superscript>+</superscript> collection was associated with thrombocytopenia, which was not significantly different between the two groups. No donor in either group developed long-term adverse effects. We conclude that both G-CSFs are comparable in terms of CD34<superscript>+</superscript> cell collection, safety and tolerability. J. Clin. Apheresis © 2005 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 07332459
- Volume :
- 20
- Issue :
- 3
- Database :
- Complementary Index
- Journal :
- Journal of Clinical Apheresis
- Publication Type :
- Academic Journal
- Accession number :
- 91399554
- Full Text :
- https://doi.org/10.1002/jca.20049